Dror Bashan - 03 Sep 2025 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: PLX
Reported as of: 03 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Sep 2025, 17:00:10 UTC
Prior SEC filing: 20 Oct 2023
Next SEC filing: 23 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Magnas, Attorney-in-Fact

Key filing fact

Dror Bashan filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 04 Sep 2025.

Key facts

This page summarizes Dror Bashan's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Sep 2025, 17:00.

Change

Previous filing in this sequence was filed on 20 Oct 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001781450 Primary reporting owner

Bashan Dror

Relationship: PRESIDENT AND CEO, Director
Address: C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, ISRAEL
Signature: /s/ Joseph R. Magnas, Attorney-in-Fact
Signature date: 04 Sep 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLX transaction

Common Stock

Award

Transaction value
Shares: +195,000
Change %: +9.1%
Price
Shares after: 2,344,418
Date: 03 Sep 2025
Ownership: By Trust
Footnotes: F1, F2

PLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 132,516
Date: 03 Sep 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +340,000
Change %
Price: $0.000000
Shares after: 340,000
Date: 03 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 340,000
Exercise price: $1.64
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

Footnote F2

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

Footnote F3

The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan.

Footnote F4

Does not include (i) options to purchase 160,000 shares of common stock at an exercise price equal to $4.69 per share that expire on June 30, 2029 and (ii) options to purchase 750,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032.